Testimony, Briefings, Statements, & Reports
Statement of NRC Senior Fellow Sonia Nagda, MD at the FDA advisory committee meeting on Lorcaserin
Sonia Nagda, a Senior Fellow at NRC, testifies at an FDA advisory committee meeting on the weight loss drug Lorcaserin. | more
What is missing from the debate over the Affordable Care Act?
The fate of the Affordable Care Act is now in the Supreme Court's hands. Much of the debate has been political instead of focusing on how the law represents much-needed reform for the health care of all Americans. | more
Statement of Paul Brown, In Support of the Ensuring Safe Medical Devices for Patients Act
Paul Brown, NRC's Government Relations Manager released a statement supporting Senator Merkley's bill, "Ensuring Safe Medical Devices for Patient Act" that requires the Food and Drug Administration (FDA) to establish a Unique Device Identifier (UDI) rule by the end of year and add medical devices to the Sentinel system. | more
Statement of Brandel France de Bravo, MPH and Diana Zuckerman, PhD on Classification for Cranial Electrotherapy Stimulators
This testimony supported the FDA's position that the available scientific evidence does not support reclassifying Cranial Electrotherapy Stimulators to a medical device category with lower risk. | more
Statement of Dr. Diana Zuckerman, Yasmin, Yaz and Other Drospirenone Birth Control Products, December 8th, 2011
Dr. Diana Zuckerman spoke at the December 8, 2011 FDA meeting on the safety of Bayer's birth control pills Yasmin and Yaz and other drospirenone birth control products, advocating for these high risk drugs to be taken off the market. | more
Statement of Dr. Diana Zuckerman, PhD regarding the Senate Aging Committee Hearing on Atypical Antipsychotic Drugs, November 30, 2011
November 30, 2011. Dr. Diana Zuckerman, the president of NRC, provided a statement for the Senate Aging Committees regarding problems with antipsychotic drugs. | more
Statement of Dr. Diana Zuckerman,PhD, at the Public Meeting on Prescription Drug User Fee Act (PDUFA) Reauthorization, October 24, 2011
Diana Zuckerman,Ph.D, president of the National Research Center for Women & Families testifies at a public hearing on the Prescription Drug User Fee Act. | more
Testimony of Dana M. Casciotti, MPH, PhD, at the FDA advisory committee meeting on breast implants, August 31, 2011
Dana Casciotti, the public health research director of NRC testifies at an FDA advisory meeting on breast implants. | more
Dr. Diana Zuckerman, testimony at FDA advisory meeting on breast implants
NRC President, Dr. Diana Zuckerman testifies at an FDA advisory hearing on breast implants. | more
Testimony of Dr. Diana Zuckerman at the FDA Obstetrics & Gynecology Devices Advisory Panel September 9, 2011
We agree with the FDA that serious adverse events from mesh are NOT rare. No man or woman wants to suffer from incontinence, but there is no doubt that the terribly painful complications can be much worse than the incontinence that initially led to surgery. And, those complications are often impossible to repair. | more
